Federal contract award
75N93020C00019
TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $7.3M |
| Current contract value | $7.3M |
| Potential contract value / ceiling | $7.6M |
| Start date | Jul 1, 2020 |
| Current end date | Jul 28, 2028 |
| Potential end date | Jul 28, 2028 |
| Latest award activity | Aug 26, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 18 of 18 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 26, 2026 | P00017 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Jun 18, 2026 | P00016 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Jul 7, 2025 | P00015 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Apr 29, 2025 | P00014 | $2.7M | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Jul 26, 2024 | P00013 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Jul 15, 2024 | P00012 | $2.5M | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Mar 1, 2024 | P00011 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| May 15, 2023 | P00010 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Apr 18, 2023 | P00009 | $830.9K | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Dec 12, 2022 | P00008 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Nov 3, 2022 | P00007 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Mar 3, 2022 | P00006 | $299.6K | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Dec 7, 2021 | P00005 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Nov 15, 2021 | P00004 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Oct 14, 2021 | P00003 | $0 | EO14042 - TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Apr 8, 2021 | P00002 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Nov 23, 2020 | P00001 | $0 | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
| Jun 29, 2020 | 0 | $904.9K | TO DEVELOP PHENOXYACETAMIDE T3SS INHIBITORS AS ADJUNCTIVE AGENTS TO ANTIBACTERIAL THERAPY FOR MDR P. AERUGINOSA INFECTIONS. |
Estimated positioning window
Jul 28, 2027 – Jan 28, 2028
Recompete signal: . Rule-based research score; positioning dates are estimates.
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2028-07-28 (642 days from calculation)
- +25 points
- 155 historical awards in this buyer and category group
- +15 points
- 18 recorded award transactions
- +10 points
- Latest award action: 2026-08-26
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.